Last reviewed · How we verify
Rosiglitazone (BRL49653C)
Rosiglitazone activates PPARγ, a nuclear receptor that regulates glucose and lipid metabolism.
Rosiglitazone activates PPARγ, a nuclear receptor that regulates glucose and lipid metabolism. Used for Type 2 diabetes.
At a glance
| Generic name | Rosiglitazone (BRL49653C) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Thiazolidinedione |
| Target | PPARγ |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Activation of PPARγ leads to increased insulin sensitivity and glucose uptake in the muscles, as well as decreased glucose production in the liver. This results in improved glycemic control and reduced risk of cardiovascular events.
Approved indications
- Type 2 diabetes
Common side effects
- Fluid retention
- Weight gain
- Headache
- Fatigue
- Muscle pain
Key clinical trials
- A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study (PHASE3)
- BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy- (PHASE3)
- A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rosiglitazone (BRL49653C) CI brief — competitive landscape report
- Rosiglitazone (BRL49653C) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI